|
Abstract #6099: Preliminary results of a phase II randomized trial of weekly or every 3-week ixabepilone in metastatic breast cancer (MBC)
Smith
II JW, Vukelja SJ, Rabe AC, Pluenneke RE, Wentworth-Hartung N,
Benaderet LB, Koutrelakos NW, Robbins GJ, Shao SH, Whittaker TL, Greco
AO, Wang Y, Boehm KA, Asmar L, Opatt D, O'Shaughnessy J
Abstract #41: Final
Overall Survival (OS) Results from the Randomised, Double-Blind,
Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus
Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line
Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC)
Miles
DW, Chan A, Romieu G, Dirix LY, Cortés J, Pivot X, Tomczak P,
Juozaityte E, Harbeck N, Steger GG, The BO17708 Study Group
Abstract #42: RIBBON-2:
A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Evaluating the Efficacy and Safety of Bevacizumab in Combination with
Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic
Breast Cancer
Brufsky A, Bondarenko IN, Smirnov V, Hurvitz S, Perez E, Ponomarova O, Vynnychenko I, Swamy R, Mu H, Rivera R
Abstract
#44: A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study
Evaluating the Efficacy and Safety of Sorafenib in Combination with
Paclitaxel as a First-Line Therapy in Patients with Locally Recurrent
or Metastatic Breast Cancer
Gradishar WJ, Kaklamani V, Sahoo TP, Lokanatha D, Raina V, Bondarde S, Jain M, Schwartzberg L
Abstract
#45: SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b
Study Evaluating the Efficacy and Safety of Sorafenib Compared to
Placebo When Administered in Combination with Capecitabine in Patients
with Locally Advanced or Metastatic Breast Cancer (BC)
Baselga
J, Grupo Españ ol de Estudio Tratamiento y Otras Estrategias
Experimentales en Tumores Só lidos, Roché H, Costa F, Getú lio Martins
Segalla J, Pinczowski H, Ma Ciruelos E, Cabral Filho S, Gó mez P, Van
Eyll B
Abstract #46: Phase
III Randomized Trial of Sunitinib (SU) Vs. Capecitabine (C) in Patients
(pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC)
Barrios
C, Liu M-C, Lee SC, Vanlemmens L, Ferrero J-M, Tabei T, Pivot X, Iwata
H, Aogi K, Brickman M, Zhang K, Kern K, Martin M
Abstract #3122: Final
Results of a Randomized Phase II Study Demonstrating Efficacy and
Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in
Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple
Negative Breast Cancer (TNBC)
O'Shaughnessy J, Osborne C, Pippen J, Patt D, Rocha C, Ossovskaya V, Sherman B, Bradley C
|
